Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Jefferam1on Feb 24, 2017 2:11pm

98 Views

Post# 25890505

RE:RE:RE:RE:RE:RE:NR says 1% of Market which means

To give you an approximate amount, I have less then 10x your holdings. But i do have several times your current holdings.

I'd love to be able to retire off this stock, but not likely to happen as I'd have to see this stock jump to $10 (my wife spends too much, jk).

Who knows maybe one day. My current target is $1-$2 sometime in 2018 if all goes well with trials. Hopefully that ends up being a conservative number :)

If we hit $2 this year, I'm selling 1/2 my shares.

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading